BRPI0620985B1 - pharmaceutical composition, and uses of triazine derivatives and insulin sensitizers - Google Patents

pharmaceutical composition, and uses of triazine derivatives and insulin sensitizers Download PDF

Info

Publication number
BRPI0620985B1
BRPI0620985B1 BRPI0620985A BRPI0620985A BRPI0620985B1 BR PI0620985 B1 BRPI0620985 B1 BR PI0620985B1 BR PI0620985 A BRPI0620985 A BR PI0620985A BR PI0620985 A BRPI0620985 A BR PI0620985A BR PI0620985 B1 BRPI0620985 B1 BR PI0620985B1
Authority
BR
Brazil
Prior art keywords
triazine derivatives
pharmaceutical composition
insulin sensitizers
sensitizers
insulin
Prior art date
Application number
BRPI0620985A
Other languages
Portuguese (pt)
Inventor
Cravo Daniel
Mesangeau Didier
Moinet Gérard
Original Assignee
Merck Patent Ges Mit Beschraenkter Haftung
Poxel S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Beschraenkter Haftung, Poxel S A S filed Critical Merck Patent Ges Mit Beschraenkter Haftung
Publication of BRPI0620985A2 publication Critical patent/BRPI0620985A2/en
Publication of BRPI0620985B1 publication Critical patent/BRPI0620985B1/en
Publication of BRPI0620985B8 publication Critical patent/BRPI0620985B8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composição farmacêutica contendo derivados de triazina e sensibilizadores de insulina, uso de ditos compostos e kit. a presente invenção refere-se a combinações de derivados de triazina e de sensibilizadores de insulina.pharmaceutical composition containing triazine derivatives and insulin sensitizers, use of said compounds and kit. the present invention relates to combinations of triazine derivatives and insulin sensitizers.

BRPI0620985A 2006-01-13 2006-12-18 pharmaceutical composition, and uses of triazine derivatives and insulin sensitizers BRPI0620985B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0600344A FR2896159B1 (en) 2006-01-13 2006-01-13 COMBINATION OF TRIAZINE DERIVATIVES AND INSULIN SENSITIZING AGENTS.
FR0600344 2006-01-13
PCT/EP2006/012185 WO2007079917A2 (en) 2006-01-13 2006-12-18 Combination of triazine derivatives and insulin sensitisers

Publications (3)

Publication Number Publication Date
BRPI0620985A2 BRPI0620985A2 (en) 2011-11-29
BRPI0620985B1 true BRPI0620985B1 (en) 2020-04-28
BRPI0620985B8 BRPI0620985B8 (en) 2021-05-25

Family

ID=36654309

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0620985A BRPI0620985B8 (en) 2006-01-13 2006-12-18 pharmaceutical composition, and uses of triazine derivatives and insulin sensitizers

Country Status (22)

Country Link
US (2) US8791115B2 (en)
EP (1) EP1971330B1 (en)
JP (1) JP5249782B2 (en)
KR (2) KR101482685B1 (en)
CN (1) CN101355933A (en)
AR (1) AR059032A1 (en)
AT (1) ATE476179T1 (en)
AU (1) AU2006334734B2 (en)
BR (1) BRPI0620985B8 (en)
CA (1) CA2640897C (en)
CY (1) CY1110789T1 (en)
DE (1) DE602006016014D1 (en)
DK (1) DK1971330T3 (en)
EA (1) EA015576B1 (en)
ES (1) ES2347177T3 (en)
FR (1) FR2896159B1 (en)
IL (1) IL192558A (en)
PL (1) PL1971330T3 (en)
PT (1) PT1971330E (en)
SI (1) SI1971330T1 (en)
WO (1) WO2007079917A2 (en)
ZA (1) ZA200806947B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2896159B1 (en) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si COMBINATION OF TRIAZINE DERIVATIVES AND INSULIN SENSITIZING AGENTS.
KR101623819B1 (en) * 2008-12-12 2016-05-24 뽁셀 에스아에스 Combination of insulin with triazine derivatives and its use for treating diabetes
EP2367802B1 (en) 2008-12-12 2016-04-20 Poxel Tetrahydrotriazine compounds for treating diseases associated with ampk activity
FR2948027A1 (en) 2009-07-17 2011-01-21 Merck Sante Sas DIHYDRO-1,3,5-TRIAZINE AMINO DERIVATIVES FOR THEIR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ISCHEMIA AND / OR REPERFUSION
FR2948026B1 (en) * 2009-07-17 2011-12-02 Merck Sante Sas DIHYDRO-1,3,5-TRIAZINE AMINO DERIVATIVES
TWI436768B (en) * 2010-06-09 2014-05-11 Poxel Treatment of type 2 diabetes
KR20120011667A (en) 2010-07-29 2012-02-08 광주과학기술원 Methods for Screening Diabetes Therapeutics
KR101271218B1 (en) * 2012-12-07 2013-06-07 광주과학기술원 Methods for Screening Diabetes Therapeutics
CN111163782A (en) 2017-10-02 2020-05-15 普克塞尔公司 Method of treating heart failure with preserved ejection fraction
CN111918655B (en) 2018-06-06 2024-05-31 博希尔公司 Methods of treating diabetic subjects with chronic kidney disease
CA3103324A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
US5885980A (en) * 1996-06-25 1999-03-23 Enrique G. Gutierrez Composition and method for treating diabetes
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
AR030920A1 (en) 1999-11-16 2003-09-03 Smithkline Beecham Plc PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MELLITUS DIABETES AND CONDITIONS ASSOCIATED WITH MELLITUS DIABETES, AND PROCEDURES FOR PREPARING SUCH COMPOSITIONS
FR2804113B1 (en) * 2000-01-26 2004-06-18 Lipha ANIMATED DIHYDRO-1,3,5-TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS
AU2001257456B2 (en) * 2000-05-01 2006-02-09 Aeropharm Technology, Inc. A core formulation
FR2853650B1 (en) * 2003-04-10 2006-07-07 Merck Sante Sas AMINE DEDOUBLING PROCESS USEFUL FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH INSULINO-RESISTANCE SYNDROME
CA2549025A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
FR2863484B1 (en) * 2003-12-11 2007-04-13 Oreal USE OF COMPOUNDS CAPABLE OF ACTING ON THE METABOLIC PATHWAY CONTROLLED BY DOPACHROME TAUTOMERASE TRP-2 AS PROTECTIVE AGENT OF MELANOCYTES OF FOLLICLE AND APPLICATIONS
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
FR2896159B1 (en) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si COMBINATION OF TRIAZINE DERIVATIVES AND INSULIN SENSITIZING AGENTS.

Also Published As

Publication number Publication date
ATE476179T1 (en) 2010-08-15
CA2640897C (en) 2015-10-20
EP1971330B1 (en) 2010-08-04
CY1110789T1 (en) 2015-06-10
DE602006016014D1 (en) 2010-09-16
BRPI0620985A2 (en) 2011-11-29
AU2006334734B2 (en) 2012-07-19
US8791115B2 (en) 2014-07-29
KR20140033498A (en) 2014-03-18
IL192558A (en) 2013-04-30
AR059032A1 (en) 2008-03-12
KR20080088630A (en) 2008-10-02
FR2896159A1 (en) 2007-07-20
PT1971330E (en) 2010-09-09
WO2007079917A2 (en) 2007-07-19
EA200801676A1 (en) 2008-12-30
ES2347177T3 (en) 2010-10-26
AU2006334734A1 (en) 2007-07-19
JP2009523142A (en) 2009-06-18
CA2640897A1 (en) 2007-07-19
CN101355933A (en) 2009-01-28
US20140050786A1 (en) 2014-02-20
FR2896159B1 (en) 2008-09-12
JP5249782B2 (en) 2013-07-31
WO2007079917A3 (en) 2007-08-30
EA015576B1 (en) 2011-10-31
SI1971330T1 (en) 2010-11-30
DK1971330T3 (en) 2010-10-25
BRPI0620985B8 (en) 2021-05-25
EP1971330A2 (en) 2008-09-24
ZA200806947B (en) 2009-11-25
PL1971330T3 (en) 2011-01-31
KR101482685B1 (en) 2015-01-14
US20100285117A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
BRPI0620985B8 (en) pharmaceutical composition, and uses of triazine derivatives and insulin sensitizers
BRPI0915084B8 (en) compound, and, pharmaceutical composition
CR10149A (en) CYTOTOXIC AGENTS UNDERSTANDING NEW TOMAIMYCIN DERIVATIVES AND THERAPEUTIC USE
UY30319A1 (en) DPP IV INHIBITORS FORMULATIONS
BRPI0814593A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND.
BRPI0716171A2 (en) compound, pharmaceutical composition and use of a compound.
BRPI0815709A2 (en) composition, pharmaceutical composition, and use of a compound.
ECSP10010722A (en) ORGANIC COMPOUNDS
BRPI0809977A2 (en) USE OF A COMPOUND, COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING
BRPI0821004A8 (en) AMINOPYRAZOLE DERIVATIVE COMPOUND, PHARMACEUTICAL COMPOSITION THAT CONTAINS IT AND USE OF IT
UY29795A1 (en) ADENINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
BRPI0609802A2 (en) compound, pharmaceutical composition and use of a compound
UY31183A1 (en) PIRAZINONA DERIVATIVES AND PROCESSES FOR THEIR PREPARATION
BRPI0810696A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND
BRPI0922364A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION AND USE OF A COMPOUND
BRPI0818804A2 (en) Pyrimidine derivative compound, pharmaceutical composition comprising it and use of such compound.
BRPI0908208A2 (en) Oxazolidinone derivative compound, drug, pharmaceutical composition containing it and use of such compound.
CL2008002295A1 (en) Alkylsulfonyl-substituted thiazolid derivative compounds; pharmaceutical composition; and use for the treatment of hepatitis c.
UY30610A1 (en) MGLUR5 MODULATORS
UY30808A1 (en) BENZOTIAZOLONAS DERIVATIVES, COMPOSITIONS CONTAINING THEM AND APPLICATIONS
BRPI0614730A2 (en) compound, pharmaceutical composition, and use of a compound
BRPI0810019A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND
ECSP088745A (en) SUBSTITUTED DERIVATIVES OF CHROMANOL AND ITS USE
BRPI0716698A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION AND USE OF A COMPOUND
BRPI0812942A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION AND USE OF A COMPOUND

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: POXEL S.A.S (FR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2703 DE 25-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.